Switchboard Raises $5M+ After Buying Livara Health

A referral once marked the edge of Switchboard Health's responsibility. Its software could match a patient with a specialist and keep the handoff moving, but it did not own the care on the other side. An oversubscribed equity financing of more than $5M and the acquisition of Livara Health move that boundary.

The transaction moves Switchboard beyond helping patients reach specialty care. It gives the company direct responsibility for delivering a portion of that care, starting with Livara's value-based MSK program. That is a larger commercial opportunity and a less forgiving operating test because clinical outcomes, care costs, and integration quality now sit beside software growth.

What Happened

Switchboard announced the Livara acquisition and financing on August 25, 2026. The company described the round as more than $5M in oversubscribed equity financing, with First Trust Capital Partners, Route 66 Ventures, A1 Health Ventures, Allumia Ventures, and Martin Ventures participating as new and returning investors. Switchboard did not disclose the exact amount above $5M, a lead investor, valuation, acquisition price, or transaction terms.

The capital is intended to support the integration of Livara and Switchboard's expansion into care delivery. Livara, formerly known as SpineZone, combines care planning, multidisciplinary virtual care, and navigation for musculoskeletal conditions. Its model includes physicians, physical therapists, and psychosocial providers, and it can operate under value-based arrangements that assume responsibility for the total cost of MSK care.

Switchboard plans to embed Livara within its referral-management and care-navigation platform. A primary care provider using Switchboard could identify an eligible patient, route that patient into Livara's program, and maintain continuity from referral through treatment. The company is attempting to turn a handoff that often breaks into a managed care pathway.

Why the Financing Matters

Switchboard launched in 2022 after Route 66 Ventures incubated the concept for nearly a year and brought in Derek Baird as co-founder and CEO. The company initially assembled a national network of virtual specialty clinics and software for providers, health plans, employers, and risk-bearing organizations. Its platform now supports specialist matching, referral tracking, authorizations, scheduling, consult-note retrieval, and care-navigation workflows.

The new financing follows a $6.5M Series Seed announced in May 2024, when First Trust Capital Partners led a round that also included Route 66 Ventures, InnovateHealth Ventures, Capital Eleven, and Ikigai Growth Partners. The August 2026 round does not come with a disclosed series label, so calling it a Seed extension or Series A would manufacture precision the company did not provide. The useful fact is that investors are funding a change in operating scope rather than a simple expansion of the existing referral product.

Switchboard reports that patient volume through its platform increased 500% during the previous nine months. That figure is company-reported, not an independently audited growth measure, but it explains the distribution logic behind the acquisition. Livara gets access to active referral workflows, while Switchboard gets a care model it can offer to patients already moving through its system.

From Navigation to Care Delivery

Referral software can create value without controlling the final clinical result. It can identify an in-network specialist, shorten administrative work, recover a consult note, and help a primary care team see whether the patient completed the handoff. Once the company begins delivering care, however, the economics change because the platform becomes accountable for more of the outcome.

Livara gives Switchboard that delivery capability in MSK care, a category where surgery, imaging, injections, rehabilitation, and delayed treatment can produce wide variations in cost. A 2024 Validation Institute review compared 850 Livara and Carelon Back and Joint Pain Program users with matched nonparticipants. Participants' post-program MSK spend was 43% lower than the nonparticipant group, and more than 75% of the difference was associated with lower use of inpatient and outpatient surgery.

That result deserves a qualifier as much as a headline. The report says participants' own per-person monthly MSK costs declined 4% from the prior year, while the larger 43% figure reflects the comparison with nonparticipants. It also notes that unmeasured differences between the groups could explain some of the observed gap, so the study supports Livara's value proposition without guaranteeing the same result across Switchboard's broader population.

The Acquisition Pattern Behind the Round

Livara is not Switchboard's first capability acquisition. In September 2025, the company acquired Conduce Health, adding predictive analytics, clinical decision support, and more precise patient-specialist matching to its platform. Conduce strengthened the decision before a referral; Livara adds the care that can follow it.

Together, those moves outline a broader product strategy. Switchboard can use data to identify a patient's needs, route the referral through administrative barriers, and directly deliver care in at least one high-cost specialty. That creates a more integrated value-based proposition for health plans and providers, but it also concentrates execution risk inside one company.

Derek Baird remains Switchboard's co-founder and CEO. Livara is led by CEO Rob Cohen and was founded by Dr. Kamshad Raiszadeh, whose MSK model predates the acquisition by nearly two decades. The announcement does not specify how many Livara team members will join Switchboard or how quickly clinical and technical operations will be integrated.

What Switchboard Must Prove Next

The first proof point is integration. Switchboard has to make Livara available through existing referral workflows without adding the administrative friction its software is designed to remove. Health plans and risk-bearing providers will also need evidence that the combined model can preserve clinical quality while reproducing credible savings across a broader patient population.

The second proof point is economic. A software company can measure referral throughput and workflow efficiency, while a care-delivery business must manage clinician capacity, patient adherence, utilization, outcomes, and contract risk. The more Switchboard assumes responsibility for total cost of care, the more its operational discipline becomes part of the product.

The new capital gives Switchboard room to attempt that transition. The financing does not prove the integrated model, and the undisclosed acquisition terms make its near-term economics difficult to judge. It does show where the company believes its next advantage lives: not only in finding the right specialist, but in accepting responsibility for what happens after the referral.